Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma Meeting Abstract
| Authors: | Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; O'Day, S.; Ascierto, P. A.; Testori, A.; Lorigan, P.; Dummer, R.; Sosman, J. A.; Garbe, C.; Lee, R. J.; Nolop, K. B.; Nelson, B.; Hou, J.; Flaherty, K. T.; McArthur, G. A. |
| Abstract Title: | Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-06-20 |
| Language: | English |
| ACCESSION: | WOS:000208865800016 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2011.29.18_suppl.lba4 |
| Notes: | Meeting Abstract: LBA4 -- Source: Wos |
